Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma.
Sixty-one dogs with appendicular osteosarcoma were treated with amputation and chemotherapy of cisplatin and doxorubicin. Serum samples were obtained before and after treatment for determination of total alkaline phosphatase (TALP) activity as well as the activities of the constituent bone (BALP), liver (LALP), and corticosteroid-induced (CALP) isoenzymes. The relationship between alkaline phosphatase activities and survival was examined by Cox proportional hazards regression analysis and Kaplan-Meier log rank analysis. Mean activity of TALP, BALP, and LALP decreased significantly after treatment (P < .001). TALP and LALP activities before treatment were significantly correlated with survival (P = .006 and .001, respectively). The correlation between BALP activity before treatment and survival approached significance (P = .054). CALP activity and TALP, BALP, and LALP activities after treatment were not significantly correlated with survival. Dogs with normal pretreatment TALP and BALP activities survived significantly longer than dogs with increased pretreatment activities (P = .001 and .003, respectively). Median survival times for dogs with normal or increased TALP activities before treatment were 12.5 and 5.5 months, respectively; and median survival times for dogs with normal or increased BALP activities before treatment were 16.6 and 9.5 months, respectively. In the design of future clinical trials involving dogs with osteosarcoma, consideration should be given to stratifying the randomization according to alkaline phosphatase activity. In addition, alkaline phosphatase activity should be a factor considered by clinicians attempting to tailor the aggressiveness of adjuvant chemotherapy to the needs of individual patients or owners.
Garzotto
C K
CK
Department of Clinical Sciences, Tufts University, School of Veterinary Medicine, North Grafton, MA 01536, USA.
Berg
J
J
Hoffmann
W E
WE
Rand
W M
WM
D000367:Age Factors; D000469:Alkaline Phosphatase / Q000097:blood*; D000671:Amputation, Surgical / Q000662:veterinary; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000601:surgery / Q000662:veterinary*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy / Q000201:enzymology* / Q000601:surgery; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D007527:Isoenzymes / Q000032:analysis; D012516:Osteosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000601:surgery / Q000662:veterinary*; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011897:Random Allocation; D015996:Survival Rate
D007527:Isoenzymes; D004317:Doxorubicin; D000469:Alkaline Phosphatase; D002945:Cisplatin